Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

Phase I/II results for TAK-754 gene therapy in severe hemophilia A

Feb. 8, 2021

Updated patient eligibility and first-in-human data for BAY-2599023

Feb. 8, 2021

SerpinPC found useful in patients with severe hemophilia

Feb. 8, 2021

Thrombin trivalent inhibitors inspired by native peptidic inhibitors from hematophagous arthropods

Feb. 8, 2021

PHA-121 demonstrates promising safety and PK profile in phase I study

Jan. 29, 2021

Xarelto approved in Japan to treat children with VTE and to prevent VTE recurrence

Jan. 26, 2021

Incyte initiates phase I/II study of INCB-000928 in patients with anemia due to MF

Jan. 26, 2021

Orladeyo approved in Japan for the prophylactic treatment of hereditary angioedema

Jan. 25, 2021

European Commission approves extension of the indication for Doptelet as treatment of ITP

Jan. 21, 2021

Shanghai Jemincare Pharmaceuticals, Jiangxi Jemincare Group present factor XIa inhibitors

Jan. 20, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Anti-C5aR1 antibodies linked to outcomes in giant cell arteritis
BioWorld Science
More effective glucocorticoid-sparing therapies are needed for the treatment of giant cell arteritis (GCA). Studies found that complement signaling pathways...
Fortvita and Innovent patent new anti-TROP2/B7-H4 ADCs
BioWorld Science
Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have jointly reported new antibody-drug conjugates (ADCs) comprising a bispecific antibody or...